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Background: To investigate the meaning of lymphadenectomy (LNE) in women with endometrial cancer (EC) for
clinical outcome and secondly to determine the impact of the method of adjuvant radiotherapy (RT) on survival as
well as to define prognostic factors.
Methods: 322 patients (pts) underwent adjuvant RT for endometrioid EC at our department from 2004 until 2012
and were included in this retrospective study. Chi-square test, LogRank test and Cox regression were used for
statistical analyses.
Results: Median age at diagnosis: 66 years. FIGO stages: FIGO I 69.4 %, FIGO II 15.3 %, FIGO III 14.5 %, FIGO IV 0.9 %.
Surgical staging: 30.6 % pelvic/paraaortic LNE, 45 % sole pelvic LNE, 8.8 % sampling of suspicious lymph nodes,
15.6 % no LNE. Adjuvant chemotherapy (ChT): 3.2 %. Sole intravaginal brachytherapy (IVB): 60.2 %. IVB + external
beam radiotherapy (EBRT): 39.8 %. 5-year local recurrence free survival (LRFS): 90.6 %, distant metastases free survival
(DMFS): 89.8 %, overall survival (OS):79.3 %. In multivariate analysis age (p = .007), pT stage (p = .029), lymph node
status (p = .003), grading (p = .011) and lymphovascular space invasion (LVSI; p = .008) remained as independent
prognostic factors for OS. Resection status (p = .01) and LVSI (p = .014) were independent prognostic factors for LRFS
and LVSI (p = .008) was the only independent prognostic factor for DMFS. There was no statistically significant
survival benefit from LNE in LRFS (p = .561), DMFS (p = .981) or OS (p = .791). 5-year LRFS in stage I and II: 96.0 and
82.9 % after sole IVB, 90.8 and 81.6 % after combined IVB/EBRT (p = .105; p = .970). 5-year OS rates for stage I and II:
86.5 and 71.3 % after sole IVB, 84.2 % and 69.2 % after combined IVB/EBRT (p = .153; p = .619).
Conclusion: Comprehensive surgical staging is rarely performed and may be omitted in women with endometrioid
EC in stages I-II. Sole IVB delivers equally good local control as combined IVB/EBRT in pts with FIGO stage I and II
disease. LVSI deserves more attention as a prognostic factor and these pts may require a combined local and
systemic therapy.
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Endometrial cancer (EC) is the most common gyneco-
logic malignancy. While therapy guidelines are widely
established and the prognosis is generally favorable, opti-
mal treatment remains controversial. In particular the
conductance of systematic lymphadenectomy (LNE) and
the role of external beam radiotherapy (EBRT) in early
stages have been actively disputed, since both therapy
modalities are known to cause substantial morbidity.
Current guidelines recommend systematic pelvic and
paraaortic LNE with investigation of at least 15 pelvic
and 10 paraaortic lymph nodes from FIGO IB onward
[1, 2]. However, clinical practice differs among surgical
centers and many patients are spared LNE or only
undergo sampling of suspicious pelvic lymph nodes
commonly omitting paraaortic lymph nodes. For radi-
ation oncologists it can be challenging to recommend
the appropriate adjuvant therapy for these patients (pts),
especially when they present with additional risk factors,
such as grade-3- histology or lymphovascular space inva-
sion (LVSI). We therefore designed this retrospective
analysis to elucidate the clinical outcome in the pts
treated with adjuvant radiotherapy (RT) at our depart-
ment and further to investigate the role of LNE and
known prognostic factors.Methods
Between 2004 and 2012 we performed adjuvant RT in
322 women with endometrioid EC at our department.
All pts were included in this retrospective study, which
was approved by the ethics committee of the University
of Heidelberg. Due to its retrospective and blinded de-
sign consent was not required. By revision of the elec-
tronic patient charts we collected detailed information
on stage, grading, resection status, LVSI, primary surgi-
cal therapy, adjuvant RT and additional adjuvant
chemotherapy (ChT). FIGO 2009 classification was
used for staging and patients were reclassified if neces-
sary. Survival analysis was done for local recurrence
free survival (LRFS), distant metastases free survival
(DMFS) and overall survival (OS). LRFS was considered
to be the time between first diagnosis and first recur-
rence within the irradiation field. DMFS was calculated
as the time from first diagnosis until distant relapse. OS
was calculated from date of first diagnosis until death
from any cause. Survival was plotted according to
Kaplan and Meier. The Log-rank test was used for uni-
variate analysis and Cox proportional hazard model
was used for multivariate analysis. The Chi-square test
was used to illustrate heterogeneity among treatment
groups. A p-value ≤ .05 was considered statistically sig-
nificant. Statistical analysis was performed with SPSS
22.0 for Windows.Results
Patients’ and tumor characteristics
Pts were first diagnosed with EC at a median age of
66 years (range: 36–92). FIGO stages were distributed as
follows: stage I 69.4 %, stage II 15.3 %, stage III 14.5 %,
stage IV 0.9 %. Positive lymph nodes (N1) were found in
9.7 %, 24.2 % had an undifferentiated tumor grading
(G3) and 16.5 % showed LVSI. Resection was incomplete
(R2) in 0.3 %, microscopically positive resection margins
(R1) were found in 2.2 % and resection status was inde-
terminable (Rx) in 5.0 % (Table 1).
Primary surgical therapy consisted of hysterectomy
and bilateral salpingo-oophorectomy in all patients. Pel-
vic and paraaortic LNE was conducted in 98 pts
(30.6 %), 144 (45.0 %) received sole pelvic LNE, 28
(8.8 %) only underwent sampling of suspicious lymph
nodes and in 50 (15.6 %) LNE was omitted. RT consisted
of EBRT in 1.8 − 2.0 Gy fractions to a cumulative dose of
40.0 − 54.0 Gy and / or high dose rate (HDR) intravagi-
nal brachytherapy (IVB) in 5.0 − 5.5 Gy fractions to a cu-
mulative dose of 10.0 − 22.0 Gy. One hundred twenty
eight (39.8 %) pts received combined IVB/EBRT and 194
(60.2 %) received IVB alone. In the IVB/EBRT group the
median total EBRT dose was 45.0 Gy and the median
total IVB dose was 10.0 Gy. Patients in the sole IVB
group received a median total dose of 22.0 Gy. Add-
itional adjuvant ChT consisting of 6 cycles of carboplatin
and paclitaxel was given to 3.1 % (n = 10) before or after
adjuvant RT. Only patients with stage III and IV disease
received ChT. A detailed overview on surgical lymph
node staging and radiotherapy for FIGO stages I-IV as
well as for FIGO stage I according to risk stratification
[3] is given in Table 2. Patients with intermediate risk
were statistically significantly more often treated with
combined EBRT/IVB when surgical lymph node staging
was omitted (p = .009, Table 2).
Survival analysis
Median follow-up was 49.5 months. Sixty-six (20.5 %)
pts died during follow-up, 27 (8.4 %) had a local recur-
rence and 26 (8.1 %) developed distant metastases. One
(0.3 %) patient presented with synchronous distant me-
tastases to the cervical lymph nodes at first diagnosis of
endometrioid EC. LRFS, DMFS and OS after 5 years
were 90.6, 89.8 and 79.3 % respectively (Fig. 1). Sites of
recurrences are shown in Table 3.
Univariate analysis
Local control was worse with higher pT stage (p = .001),
positive regional lymph nodes (p < .001), positive or inde-
terminable resection margins (p < .001) and LVSI (p = .001;
Fig. 2)
Distant metastases occurred earlier in pts with higher
FIGO stage (p = .001), higher pT stage (p < .001) and
Table 2 Treatment according to (A) FIGO stages and (B) risk
stratification
(A) FIGO stages n % χ2
FIGO I (N = 222)
LNE IVB 143 76.9 % p = .194
IVB + EBRT 43 23.1 %
No LNE IVB 24 66.7 %
IVB + EBRT 12 33.3 %
FIGO II (N = 49)
LNE IVB 21 51.2 % p = .478
IVB + EBRT 20 48.8 %
No LNE IVB 3 37.5 %
IVB + EBRT 5 62.5 %
FIGO III (N = 46)
LNE IVB 3 7.2 % p = .580
IVB + EBRT 39 92.8 %
No LNE IVB 0 0 %
IVB + EBRT 4 100 %
FIGO IV (N = 3)
LNE IVB 0 0 % NA
IVB + EBRT 2 100 %
No LNE IVB 0 0 %
IVB + EBRT 1 100 %
(B) Risk stratification n % χ2
Low risk (N = 77)
LNE IVB 55 94.8 % p = .988
IVB + EBRT 3 5.2 %
No LNE IVB 18 94.7 %
IVB + EBRT 1 5.3 %
Intermediate risk (N = 121)
LNE IVB 74 70.5 % p = .009
IVB + EBRT 31 29.5 %
No LNE IVB 6 37.5 %
IVB + EBRT 10 62.5 %
High risk (N = 24)
LNE IVB 14 60.9 % p = .227
IVB + EBRT 9 39.1 %
No LNE IVB 0 0 %
IVB + EBRT 1 100 %
Table 1 Patients’ and tumor characteristics
Age N = 322
median 66 years
range 36 − 92 years
n %
FIGO N = 320
IA 104 32.5 %
IB 118 36.9 %
II 49 15.3 %
IIIA 13 4.1 %
IIIB 4 1.3 %
IIIC 29 9.1 %
IVA 2 0.6 %
IVB 1 0.3 %
pT stage N = 320
T1 237 74.1 %
T2 58 18.1 %
T3 24 7.5 %
T4 1 0.3 %
Nodal status N = 320
N0 289 90.3 %
N1 31 9.7 %
Grading N = 322
G1 69 21.4 %
G2 175 54.3 %
G3 78 24.2 %
LVSI N = 322
no LVSI 269 83.5 %
LVSI 53 16.5 %
Resection N = 322
R0 298 92.5 %
R1 7 2.2 %
R2 1 0.3 %
RX 16 5.0 %
Metastases N = 320
M0 319 99.7 %
M1 1 0.3 %
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vanced FIGO stage (p < .001), higher pT stage (p < .001),
positive regional lymph nodes (p < .001), higher grading
(p = .001), positive or indeterminable resection margins
(p < .001) and LVSI (p < .001; Fig. 2) were associated with
shorter OS. There was no statistically significant survival
benefit from LNE in LRFS, DMFS or OS (Fig. 3). Sole
IVB was not inferior to combined IVB/EBRT in early
stages independent of the conducted surgical lymphnode staging and independent of the risk stratification.
Five-year local control in stage I was 96.0 % after sole
IVB and 90.8 % after combined IVB/EBRT (p = .105).
Five-year OS rates in stage I for sole IVB and combined
IVB/EBRT were 86.5 % and 84.2 % respectively
(p = .153). For stage II 5-year LRFS was 82.9 % after sole
IVB and 81.6 % after IVB/EBRT (p = .970). Five-year OS
Table 3 Sites of recurrences
n
Local recurrences N = 27
paraaortic lymph nodes 8
vaginal pole 12
pelvic floor and wall 7
Distant recurrences N = 26
lungs 12
liver 6
skin 3
abdominal wall 2
inguinal lymph nodes 3
cervical lymph nodes 2
retroperitoneal lymph nodes 2
adrenals 2
intestine 3
mediastinum 4
bone 3
peritoneum 4
brain 2
Fig. 1 Kaplan-Meier survival curves for a LRFS, b DMFS, c OS
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and combined IVB/EBRT groups (p = .619). Additional
adjuvant ChT did not statistically significantly effect sur-
vival in all 3 endpoints.Multivariate analysis
Age (p = .017; HR 1.88 [95 % CI 1.12 − 3.16]), pT stage
(p = .029; HR 2.13 [1.08 − 4.21]); lymph node status
(p = .003; HR 2.74 [95 % CI 1.40 − 5.37]), grading (p = .011;
HR 1.99 [95 % CI 1.77 − 3.39]) and LVSI (p = .008; HR
2.22 [95 % CI 1.24 − 3.98]) were revealed as independent
prognostic factors for OS in Cox regression model. LVSI
was the only independent prognostic factor (p = .008; HR
2.22 [95 % CI 1.24 − 3.98]) for DMFS. Resection status
(p = .01; HR 3.96 [95 % CI 1.39 − 11.28]) and LVSI
(p = .014; HR 2.87 [95 % CI 1.25 − 7.10]) remained as
independent prognostic factors for LRFS.
Observed acute toxicities
Women receiving combined IVB/EBRT showed a sub-
stantially higher rate of acute gastrointestinal (GI) toxic-
ities compared to those with sole IVB (37.5 % vs. 8.7 %).
Only one patient receiving combined IVB/EBRT devel-
oped a grade 3 acute GI toxicity (enterocolitis) requiring
hospitalization. Regarding acute genitourinary (GU) tox-
icities we observed similar rates in the IVB/EBRT and
sole IVB groups (57.8 % vs. 56.2 %). None developed
acute GU toxicities ≥ grade 3.
Discussion
The conductance of systematic LNE, especially in early
stage EC, has been actively disputed over the past years
[4]. Two randomized trials did not find a survival benefit
from systematic pelvic LNE in EC [5, 6]. Arguable, in
Fig. 2 Kaplan-Meier survival curves for LVSI and a LRFS, b DMFS,
c OS
Fig. 3 Kaplan-Meier survival curves for LNE and a LRFS, b DMFS,
c OS
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groups showed a high proportion of low-risk pts and ad-
juvant therapy was not standardized. The Japanese
SEPAL trial showed a significantly prolonged OS in
intermediate- and high risk patients who underwent
combined pelvic and paraaortic LNE, whereas OS was
not prolonged in low-risk pts [7]. The uncertainty over
the therapeutic value of systematic LNE has led to a
point where surgical practice differs among centers sub-
stantially and many surgeons prefer an individual risk
assessment over the systematic LNE recommended in
current guidelines [1, 2]. A recent report from Bogani
et al. describes the clinical practice regarding LNE at the
Mayo Clinic in Minnesota [8]. The colleagues from
Rochester only perform systematic pelvic and paraaortic
LNE in pts with >50 % myometrial invasion, non-
endometrioid histology or both. Additionally paraaortic
LNE is conducted when positive pelvic lymph nodes are
found, while pelvic LNE is conducted based on involve-
ment of the uterine cervix, undifferentiated grading and
tumor diameter > 2 cm. This practice seems to be sup-
ported by a recent Surveillance, Epidemiology, and End
Results database analysis from Vargas et al. on risk fac-
tors for lymph node metastases in EC [9]. The cohort of
women treated with adjuvant RT at our department was
also very heterogeneous regarding surgical staging and
only a minority underwent comprehensive surgical sta-
ging as demanded in current guidelines; however we
were unable to detect any statistically significant benefit
from surgical lymph node investigation for all 3 end-
points (LRFS, DMFS and OS) in our current study. This
was surprising, since we were able to demonstrate a sig-
nificantly prolonged OS after LNE in pts with type II EC
previously [10]. The groups of pts with stage IIIA and
IIIB as well as stage IV disease in our current study were
too small for LNE- and RT-stratified subgroup analysis
(Table 2), but for patients with stage I and II disease we
were able to confirm these results in separate analyses.
Women with intermediate risk more often received
combined IVB/EBRT when LNE was omitted in our
study; this, however, did not have a statistically signifi-
cant influence on survival as well. Our results are gener-
ally supported by the findings of the PORTEC trials
where no routine LNE was required [11, 12]. We believe
that surgical lymph node staging may be omitted in pts
with type I EC in stages I-II and we further believe that
women who did not receive systematic LNE and are
without clinical suspicion of regional lymph node metas-
tases may be treated as if they had undergone compre-
hensive surgical staging.
We found our results regarding local control, disease-
free and overall survival to generally be in line with a
recent retrospective study on postoperative RT from
Switzerland [13]. Several randomized trials haveinvestigated the role of adjuvant RT in EC [11, 14–16].
All showed a significantly improved local control; even in
the treatment of recurrences [17]. Since the Norwegian
trial from Aalders et al. [14], published in 1980, efforts
have been made to reduce RT-associated morbidity by de-
fining subgroups of pts which do not require EBRT and
may benefit from IVB alone [12, 18–22]. The PORTEC-2
trial proved that IVB alone provides similar local control
rates as combined IVB/EBRT treatment in pts with higher
risk profile in early stages while toxicity is substantially re-
duced [12, 23]. The women with FIGO stage I and stage II
disease in our study cohort also had an equally good local
control and OS after sole IVB and combined IVB/EBRT.
Far too few patients received additional adjuvant ChT to
be able to draw any conclusions on its effect on survival.
In multivariate analysis age over 66 years was associ-
ated with a shorter OS (p = .017). This is in agreement
with a study from Benedetti Panici et al. who reported a
reduced overall and cancer specific survival in women
over 65 years [24]. Other independent prognostic fac-
tors for OS in our analysis were pT stage (p = .029),
lymph node status (p = .003) and grading (p = .011). For
local control we found resection status (p = .01) to be an
independent prognostic factor. Interestingly LVSI was
the only independent prognostic factor that was found
in all 3 endpoints (LRFS [p = .014], DMFS [p = .049], OS
[p = .008]) and it was the only independent prognostic
factor for DMFS. Previous studies have already re-
ported on the prognostic relevance of LVSI in EC or
considered the presence of LVSI a feature of higher
risk [13–15, 25–27]. We believe that LVSI deserves
more attention as a prognostic factor and that these
women may be in need for a combined local and sys-
temic treatment approach.
The observed acute GI toxicities were moderate and in
line with a previous report, considering that intensity
modulated radiotherapy was available only for patients
treated in more recent years [28]. The relatively large
proportion (>50 %) of documented acute GU toxicities
in both groups is owed to the inclusion of asymptomatic
grade 1 vaginal erythema.
Conclusion
Comprehensive surgical staging is rarely performed and
may be omitted in women with type I EC in stages I-II.
Sole IVB provides equally good local control as com-
bined IVB/EBRT in stages I and II. Women with LVSI
may be in need for a combined local and systemic ther-
apy and LVSI should be included as a major risk factor
in future randomized trials.
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